In our role as a global health leader, Johnson & Johnson is closely monitoring the COVID-19 (coronavirus) situation and taking steps to help prevent the spread of the virus as well as exploring the potential for a vaccine.

We have robust business continuity plans in place across our global supply chain network to prepare for unforeseen events and to meet the needs of the patients, customers and consumers who depend on our products.

Janssen continues to supply its medicines in Australia and while this remains a dynamic situation, we do not foresee pharmaceutical supply interruptions related to COVID-19 at this time.

As a leader in global health, our top priority remains our patients, customers and employees. We are partnering with global and local health authorities to collaborate in addressing the immediate and long term needs to ensure a sustainable supply of our critical medicines as well as researching potential vaccines and therapeutics.

We will remain on the front line of this health crisis, bringing our full resources and minds to combat it.

Contacting Janssen 

As a leader in global health, our top priority remains our patients, customers and employees.   

We remain available via our normal channels: https://www.janssen.com/australia/contact-us  

Government information and resources

• Department of Health, Australian Federal Government www.health.gov.au/resources/collections/novel-coronavirus-2019-ncov-resources   

• National Coronavirus Health Information Line 1800 020 080. If translation or interpreting services are needed, call 131 450.

• Health Direct www.healthdirect.gov.au/coronavirus